【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1505次   下载 1956 本文二维码信息
码上扫一扫!
脂蛋白相关性磷脂酶A2活性能反映冠状动脉粥样硬化病变程度
刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江,LIUJia-xing,ZHENGXing,QINYong-wen,DINGJi-jun,ZHAOXian-xian,CAOJiang
0
()
摘要:
目的:探讨人血浆脂蛋白相关性磷脂酶A2(Lp-PLA2)活性与冠状动脉病变严重程度和稳定性的关系.方法:对180例可疑冠心病患者进行冠脉造影,以病变支数和Gensini积分评价冠脉病变严重程度,根据造影结果分为冠心病组(112例)与对照组(68例).冠心病患者再分别根据临床类型、冠脉病变支数、Gensini积分进行分组.所有患者在造影前均测定血浆Lp-PLA2活性、白细胞(WBC)数、超敏C反应蛋白(hsCRP)、血脂、血压、体质量指数等指标,同时采集年龄、性别、吸烟史、高血压病史及糖尿病史等资料.用统计学方法对各亚组Lp-PLA2活性、WBC、hsCRP进行比较,并计算Lp-PLA2活性与WBC、hsCRP及冠心病传统危险因素的相关系数.结果:冠心病患者血浆Lp-PLA2活性显著高于对照组(P<0.01).Lp-PLA2活性在稳定型心绞痛和急性冠脉综合征患者间无显著差别;Lp-PLA2活性随着冠脉病变支数和Gensini积分的增加而升高.血浆Lp-PLA2活性与TC、LDL-C呈明显正相关,与HDL-C呈负相关,与WBC微弱相关,与hsCRP无相关.结论:血浆Lp-PLA2活性能反映冠状动脉粥样硬化病变的严重程度,与冠脉病变稳定性无关.
关键词:  脂蛋白相关性磷脂酶A2、冠状动脉硬化、冠状动脉疾病
DOI:10.3724/SP.J.1008.2006.00391
基金项目:
Lipoprotein-associated phospholipase A2 as a predictor for severity of coronary atherosclerosis
刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江,LIU Jia-xing,ZHENG Xing,QIN Yong-wen,DING Ji-jun,ZHAO Xian-xian,CAO Jiang
()
Abstract:
Objective:To investigate whether plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity correlates with severity and stability of coronary atherosclerosis and other established cardiovascular risk factors. Methods.. Coronary angiography (CAG) was performed in 180 hospitalized patients who were suspected as having coronary heart disease (CHD). The severity of pathological changes of the coronary artery was assessed by the number of diseased coronary branches and Gensini's score. According to the results of CAG, the 180 patients were divided into 2 groups: CHD group (n=112) and non-CHD group (n=68). The CHD patients were further divided into subgroups according to the clinical types, the number of diseased coronary branches and Gensini's score. Lp-PLA2 activity, white blood cell (WBC) count, high sensitive C reactive protein (hsCRP), lipids, blood pressure and body mass index were measured. The age, sex and prior medical histories including hypertension, diabetes mellitus and smoking status were obtained before CAG in all patients. Lp-PLA2, WBC count and hsCRP were compared statistically between the subgroups, and correlation coefficients of Lp-PLA2 activity with WBC count, hsCRP and other conventional risk factors for CHD were calculated. Results: Plasma Lp-PLA2 activity in CHD patients was significantly higher than that in controls (P〈0.01). No significant difference was found in Lp-PLA2 activity between patients with acute coronary syndrome and stable angina pectoris. Lp-PLA2 activity increased with the increasing number of diseased coronary branches and Gensini's score. Plasma Lp-PLA2 activity was positively correlated with TC and LDL-C, negatively correlated with HDL-C, weakly correlated with WBC count, and not correlated with hsCRP. Conclusion: Plasma Lp-PLA2 activity can be used as a parameter to predict pathological severity of coronary atherosclerosis, though it is not associated with stability of pathological changes of the coronary artery.
Key words:  lipoprotein-associated phospholipase A2  coronary arteriosclerosis  coronary disease